The role of vascular endothelial growth factor in angiogenesis

Acta Haematologica

Volumn 106, Issue 4, 2001, Pages 148-156

  Ferrara, Napoleone ^a   Gerber, Hans Peter ^a  

^a GENENTECH INC   (United States)

Author keywords

Angiogenesis; Apoptosis; Endothelium; Retinopathy; Tumor growth; Tyrosine kinases; Vascular endothelial growth factor

Indexed keywords

MITOGENIC AGENT; NEUROPILIN 1; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CARCINOGENESIS; EMBRYO DEVELOPMENT; ENCHONDRAL OSSIFICATION; FEMALE GENITAL SYSTEM; HEMATOPOIESIS; HUMAN; HYPOTHESIS; NONHUMAN; PATHOPHYSIOLOGY; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035704913     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046610     Document Type: Article

References (103)

1. The biology of vascular endothelial growth factor
2. Role of vascular endothelial growth factor in the regulation of angiogenesis
3. Signaling angiogenesis and lymphangiogenesis
4. Vascular endothelial growth factor is a secreted angiogenic mitogen
5. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
6. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
7. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins
8. Clinical applications of angiogenic growth factors and their inhibitors
9. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells
10. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor
11. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells
12. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro
13. Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro
14. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system
15. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
16. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells
17. VEGF regulates endothelial cell survival by the PI 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
18. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
19. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
20. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis
21. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
22. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
23. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
24. Fibrin containing gels induce angiogenesis: Implications for tumor stroma generation and wound healing
25. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability
26. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family
27. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
28. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor
29. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
30. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
31. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
32. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF
33. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
34. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, high affinity binding to Flt-1 but not to Flk-1/KDR
35. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
36. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
37. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration
38. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1
39. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1
40. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
41. Receptors for collapsin/semaphorins
42. Collapsin: A protein in brain that induces collapse and paralysis of neuronal growth cones
43. Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: Functional competition of collapsin-1 and vascular endothelial growth factor-165
44. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4
45. Roles of ephrinB ligands and EphB receptors in cardiovascular development: Demarcation of arterial/venous domains, vascular morphogenesis, sprouting angiogenesis
46. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
47. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
48. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelila growth factor isoforms VEGF164 and VEGF188
49. A cardiac myocyte VEGF paracrine pathway is required to maintain cardiac function
50. VEGF is required for growth and survival in neonatal mice
51. Inducible gene targeting in mice
52. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
53. Vascular endothelial growth factor (VEGF) in cartilage neovascularization and chondrocyte differentiation: Auto-paracrine role during endochondral bone formation
54. The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle
55. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
56. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis
57. Vascular endothelial growth factor is expressed in rat corpus luteum
58. Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary
59. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally-mediated angiogenesis
60. Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: Rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth
61. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade
62. Vascular endothelial growth factor is essential for corpus luteum angiogenesis
63. Preclinical safety evaluation of rhuMAb VEGF, an antiangiogenic humanized monoclonal antibody
64. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor
65. Ovarian hyperstimulation syndrome: Report of one case with notes on pathogenesis and treatment
66. Pathophysiology of the ovarian hyperstimulation syndrome
67. Vascular endothelial growth factor as a capillary permeability agent in ovarian hyperstimulation syndrome
68. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome
69. The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome
70. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome
71. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamber
72. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants
73. Tumor angiogenesis: Therapeutic implications
74. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
75. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders
76. Anti-vascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis
77. Flk-1 as a target for tumor growth inhibition
78. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
79. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
80. A randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus Carboplatin/Paclitaxel (CP) to CP Alone in Patients with Stage IIIB/IV NSCLC
81. A Randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) plus 5-Fluorouracil/Leucovorin (FU/LV) to FU/LV Alone in Patients with Metastatic Colorectal Cancer
82. A Phase II Trial of Single-Agent rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelila Growth Factor) in Patients with Relapsing Metastatic Breast Cancer
83. A Phase I/II Study of SU5416 in Combination with 5-FU/Leucovorin in Patients with Metastatic Colorectal Cancer
84. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells. Possible role in the hemato-poietic microenvironment
85. Flk-1 expression defines a population of early embryonic hematopoietic precursors
86. KDR receptor: A key marker defining hemato-poietic stem cells
87. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
88. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
89. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
90. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
91. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia
92. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
93. Angiogenic factors in multiple myeloma: Higher levels in bone marrow than in peripheral blood
94. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes
95. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
96. Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen
97. VEGF antagonism reduces cerebral edema formation and tissue damage following ischemic-reperfusion injury in the mouse brain
98. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plas-minogen activator activity in endothelial cells
99. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, impaired recovery from cardiac ischemia
100. Double Blind, Placebo Controlled Trial of Recombinant Human Vascular Endothelial Growth Factor: The VIVA Trial
101. The role of angiogenesis in bone regeneration